Q1 2025 Fresenius Medical Care AG Earnings Call Transcript
Key Points
- Fresenius Medical Care AG (FMS) reported strong organic revenue growth of 5% in Q1 2025, driven by both Care Delivery and Care Enablement segments.
- The FME25 transformation program delivered EUR68 million in additional sustainable savings, contributing to the company's financial health.
- Operating income grew by 11%, positioning the company well for future quarters.
- The net leverage ratio improved to 2.8x, below the self-imposed target range, indicating strong financial discipline.
- Care Enablement segment achieved a margin of 8.3%, entering its target margin band of 8% to 12% for the first time.
- The severe flu season led to increased missed treatments, impacting same market treatment growth in the U.S.
- Divestitures negatively impacted revenue development by 260 basis points.
- Special items, including costs related to portfolio optimization and the FME25 transformation program, negatively affected group operating income by EUR126 million.
- Labor and inflation costs offset some of the earnings developments in the Care Delivery segment.
- The company faced a headwind from one less dialysis day in the quarter, affecting absolute volume development and utilization.
Ladies and gentlemen, welcome to the Q1 2025 of Fresenius Medical Care Earnings Conference Call. I'm Sandra, the Chorus Call operator. (Operator Instructions) The conference is being recorded. (Operator Instructions) The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Dr. Dominik Heger. Please go ahead, sir.
Thank you, Sandra. I would like to welcome everyone to our earnings call for the first quarter 2025. I know that this is a very tough day with many companies in the sector reporting today. Nevertheless, thank you for joining us today. As always, I would like to start out the call by mentioning our cautionary language that is in our safe harbor statement as well as in our presentation and in all the materials that we have distributed earlier today.
For further details concerning risks and uncertainties, please refer to these documents and to our SEC filings. As always, we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
